What the trial was testing
The TARGET-HTN enrolled 200 patients with hypertension. The study was sponsored by Mineralys Therapeutics Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Lorundrostat lowered systolic blood pressure by nearly 10 mm Hg more than placebo in people with treatment-resistant hypertension.
JAMA · 2023 · NCT05001945
These findings — that blood pressure dropped an extra 10 points with the 50 mg dose compared to placebo — were published in the JAMA and represent the headline result of the study.
Researchers tracked outcomes across 200 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with hypertension, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was an initial testing study and lorundrostat is not yet FDA-approved. The results were promising for people whose blood pressure doesn't respond well to standard medications. If you have uncontrolled high blood pressure despite taking multiple drugs, talk to your doctor about whether you might qualify for a clinical trial testing this approach.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open hypertension trials
Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension
This trial aims to evaluate the effectiveness of a Behavioral Modification Working (BMW) Toolkit in improving glycemic control and blood pressure among pregnant women diagnosed with both GDM and PIH.
A Trial of Hydrus Microstent Versus Goniotomy
The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are: * How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare? * How do the safety profiles of these three microinvasive glaucoma surgeries compare? Participants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.